This Specialized Program of Research Excellence (SPORE) grant is intended to support multi-project, interdisciplinary and multi-institutional translational research in glioblastoma. The governance structure of this Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE grant will provide the foundation for the implementation, execution and ultimate success of all projects and cores. The Administration Core will serve as the """"""""hub"""""""" for this governance structure and will aim to achieve a number of specific objectives as defined below. We will implement a plan to establish experienced, centralized program leadership and administration. The Glioma SPORE Director and Co-Director are senior administrators and researchers who have worked together on prior DF/HCC inifiatives and who provide strong, complementary leadership for the grant. The trans-institutional administrative team consists of senior personnel at DF/HCC institutions who have worked together effecfively in the preparafion of this grant applicafion. We have incorporated two senior clinical and imaging scientists into the Administrafion Core to supervise Glioma SPORE-specific clinical trials and imaging studies, respectively, and to enable this Glioma SPORE to capitalize on existing DF/HCC Cores to support these types of studies. We will establish an effective internal and external committee structure to provide expertise, advice and oversight of the program. Each of the committees consists of collaborative, complementary members who have already worked together in the preparation of this SPORE application. A series of regular Glioma SPORE meetings involving both administrative and scientific SPORE staff are planned to facilitate close collaboration, troubleshooting and monitoring of the SPORE program. We will establish an effective internal and external communicafions program, which will include a Glioma SPORE-specific component. An established and extensive DF/HCC communications infrastructure will be utilized to promote open, regular, trans-institutional communicafion regarding SPORE opportunities and activities. We will implement an active SPORE program to enhance participation by underrepresented minorities and women.

Public Health Relevance

Glioblastomas are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between 15-34 years of age ( In the fullness of time, the work that we propose with targeted therapies could change the standard of care and improve patient outcomes for these tumors. The Administrafion Core will serve as the hub for the governance of this SPORE research program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Arnold, Julia T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Kloepper, Jonas; Riedemann, Lars; Amoozgar, Zohreh et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81
Flavahan, William A; Drier, Yotam; Liau, Brian B et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529:110-4
Curry Jr, William T; Gorrepati, Ramana; Piesche, Matthias et al. (2016) Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res 22:2885-96
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167
Verreault, Maite; Schmitt, Charlotte; Goldwirt, Lauriane et al. (2016) Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res 22:1185-96
Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6
Tateishi, Kensuke; Iafrate, A John; Ho, Quan et al. (2016) Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22:4452-65
Cizmecioglu, Onur; Ni, Jing; Xie, Shaozhen et al. (2016) Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife 5:
Fathi, Amir T; Nahed, Brian V; Wander, Seth A et al. (2016) Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist 21:214-9

Showing the most recent 10 out of 44 publications